- Oral presentation
- Open access
- Published:
O10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old)
Clinical and Translational Allergy volume 4, Article number: O10 (2014)
Background
Rupatadine is an anti-H1/PAF antagonist that has proven to be effective and safe in adults/adolescents for Allergic Rhinitis (AR) and Urticaria. In addition, Rupatadine has been recently licensed for the symptomatic treatment of AR in children aged 6-11 years. The aim of this study was to assess the efficacy and safety of Rupatadine oral solution in children with Chronic Spontaneous Urticaria (CSU).
Methods
A randomized, double blind, multicenter, parallel group, placebo and active controlled clinical trial was conducted in children aged 2-11 year suffering from CSU. Patients were randomly allocated to one of the treatment groups: Rupatadine 1mg/mL, Desloratadine 0.5mg/ml, or placebo oral solutions. Dosing was done according to patients’ weight (2.5 ml > 10 Kg - 25 Kg or 5 ml > 25 Kg). Patients received the study medication during 6 weeks (42 days) and symptoms were scored daily in the patient diary. There was a safety follow up period of 6 weeks (42 days) after the end of treatment. The primary efficacy variable was the change in the 7-day cumulative children adapted Urticaria Activity Score (UAS7) over the treatment period. Other efficacy assessments included the mean number of wheals (MNW) score, mean pruritus (MPS) score and Children Dermatology Life Quality Index (CDLQI). Adverse events were recorded through the study (84 days).
Results
A total of 199 patients were included in the ITT analysis: 63 in the Rupatadine group, 69 in the Desloratadine group, and 67 in the placebo group. The UAS7 was found to be significantly reduced in the Rupatadine group (-55.8%; p=0 .001) and the Desloratadine group (-48.4%; p= 0.013) as compared to placebo (-30.3%). Also, CDLQI scores were significantly improved in both active treatment groups as compared to placebo. The overall incidence of adverse events was similar among treatments groups.
Conclusion
Rupatadine, in accordance with the current CSU guideline recommendations, is an effective and safe choice in CSU in 2-11 yr children.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Potter, P., Mitha, E., Barkai, L. et al. O10 - Rupatadine is effective and safe in the treatment of Chronic Spontaneous Urticaria (CSU) in pediatric patients (2-11 years old). Clin Transl Allergy 4 (Suppl 1), O10 (2014). https://doi.org/10.1186/2045-7022-4-S1-O10
Published:
DOI: https://doi.org/10.1186/2045-7022-4-S1-O10